New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
10:02 EDTGSK, CAT, SPF, LEN, ERIC, ANF, HOV, SWIR, GPC, CGV, TSN, PLXT, FITB, BREOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Abercrombie & Fitch (ANF) upgraded to Outperform from Market Perform at BMO Capital... BRE Properties (BRE) upgraded to Neutral from Sell at Goldman... CGG Veritas (CGV) upgraded to Overweight from Neutral at JPMorgan... Caterpillar (CAT) upgraded to Outperform from Market Perform at BMO Capital... Ericsson (ERIC) upgraded to Buy from Hold at Deutsche Bank... Fifth Third Bancorp (FITB) upgraded to Outperform from Market Perform at Wells Fargo... Genuine Parts (GPC) upgraded to Buy from Hold at BB&T... Lennar (LEN) upgraded to Buy from Neutral at Compass Point... PLX Technology (PLXT) upgraded to Buy from Hold at Wunderlich... Sierra Wireless (SWIR) upgraded to Outperform from Sector Perform at RBC Capital... Standard Pacific (SPF) upgraded to Buy from Neutral at Compass Point... Tyson Foods (TSN) upgraded to Buy from Underperform at BofA/Merrill... Hovnanian (HOV) upgraded to Neutral from Sell at Compass Point... GlaxoSmithKline (GSK) upgraded to Overweight from Equal Weight at Barclays... Caterpillar (CAT) upgraded to Buy from Outperform at CLSA.
News For ANF;BRE;CGV;ERIC;FITB;GPC;LEN;PLXT;SWIR;SPF;TSN;HOV;GSK;CAT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 22, 2015
15:01 EDTERICWi-LAN says Ericsson granted motion for summary judgment on three patents
Subscribe for More Information
10:52 EDTGSKJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
May 21, 2015
07:37 EDTGSKPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 20, 2015
11:06 EDTGPCGenuine Parts management to meet with Wedbush
Meetings to be held in New York May 21-22 hosted by Wedbush.
10:37 EDTCATCaterpillar April update seems negative for earnings power, says Wells Fargo
Subscribe for More Information
10:00 EDTFITBOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Achillion (ACHN) downgraded on valuation at JMP Securities... Ashland (ASH) downgraded to Equal-Weight from Overweight at First Analysis... Bank of Nova Scotia (BNS) downgraded to Underperform from Neutral at BofA/Merrill... Braskem (BAK) downgraded to Neutral from Overweight at JPMorgan... Comerica (CMA) downgraded to Underperform at Baird... Crestwood Midstream (CMLP) downgraded to Neutral from Buy at Ladenburg... Fifth Third (FITB) downgraded to Neutral from Outperform at Baird... Keurig Green Mountain (GMCR) downgraded to Hold from Buy at Argus... Keysight Technologies (KEYS) downgraded to Neutral from Outperform at Baird... Leju (LEJU) downgraded to Underperform from Buy at CLSA... Marrone Bio (MBII) downgraded to Hold from Buy at Jefferies... Southwest (LUV) downgraded to Neutral from Buy at Buckingham... SunTrust (STI) downgraded to Market Perform from Outperform at Keefe Bruyette... Western Alliance (WAL) downgraded to Market Perform from Outperform at Keefe Bruyette.
09:14 EDTCATCaterpillar reports retail machines sales down 11% in three months end April
Subscribe for More Information
08:10 EDTTSNTyson Foods repeats FY15 adjusted EPS view $3.30-$3.40, consensus $3.44
Subscribe for More Information
07:46 EDTGSKDeutsche Bank positive on potential Pfizer, GSK merger
Deutsche Bank analyst Gregg Gilbert believes a large foreign deal for Pfizer (PFE) may make sense and says a buyout of GlaxoSmithKline (GSK) could be "materially" accretive to earnings while improving the company's tax situation over time. Gilbert assumes a $60 per share buyout price for GlaxoSmithKline in a research note this morning titled "Introducing 'PfizerKline'". The stock closed yesterday up 2c to $44.68. Gilbert reiterates a Buy rating on Pfizer with a $41 price target. Shares ended yesterday up 23c to $34.21.
06:36 EDTFITBFifth Third downgraded to Neutral on valuation at Baird
As previously reported, Baird downgraded Fifth Third to Neutral from Outperform. The firm maintained its $21 price target and downgraded shares due to balanced risk reward.
06:16 EDTFITBFifth Third downgraded to Neutral from Outperform at Baird
Subscribe for More Information
May 19, 2015
17:16 EDTTSNTyson Foods awarded $194.79M government contract
Subscribe for More Information
14:51 EDTCATCaterpillar management to meet with William Blair
Subscribe for More Information
09:58 EDTFITBOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Ascena Retail (ASNA) upgraded to Outperform from Market Perform at FBR Capital... Enphase Energy (ENPH) upgraded to Strong Buy from Buy at Needham... Fifth Third (FITB) upgraded on Vantiv outlook at Oppenheimer... Hortonworks (HDP) upgraded to Overweight from Equal Weight at Barclays... MasterCard (MA) upgraded to Overweight from Sector Weight at Pacific Crest... NetEase.com (NTES) upgraded to Buy from Neutral at Citigroup... Panera Bread (PNRA) upgraded to Outperform from Market Perform at Cowen... Potash (POT) upgraded to Market Perform from Underperform at Cowen... Reed Elsevier (RUK) upgraded to Buy from Neutral at Goldman... Royal Caribbean (RCL) upgraded to Overweight from Neutral at JPMorgan... Sysco (SYY) upgraded at Credit Suisse... THL Credit (TCRD) upgraded to Buy from Hold at Deutsche Bank... Take-Two (TTWO) upgraded to Buy from Neutral at Sterne Agee CRT... Tempur Sealy (TPX) upgraded on Sealy gross margin improvement at Longbow... TriState Capital (TSC) upgraded to Outperform from Market Perform at Keefe Bruyette... Xilinx (XLNX) upgraded to Overweight from Sector Weight at Pacific Crest.
09:25 EDTGSKGlaxoSmithKline asthma drug overused, risks underappreciated, ProPublica says
Subscribe for More Information
07:45 EDTFITBFifth Third upgraded on Vantiv outlook at Oppenheimer
Subscribe for More Information
07:34 EDTHOV, LENJPMorgan to hold a conference
Subscribe for More Information
06:55 EDTGSKGenocea could be takeover target after data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Genocea Biosciences (GNCA) will report positive Phase II GEN-003 post-immunization results late in Q2. GEN-003 is a therapeutic vaccine for genital herpes targeting Herpes Simplex Virus Type 2. Positive GEN-003 data could position Genocea as a potential acquisition target by a larger vaccine player, Tenthoff tells investors today in a research note. Large vaccine makers include Sanofi (SNY), Merck (MRK), GlaxoSmithKline (GSK), Pfizer (PFE) and Novartis (NVS). The analyst reiterates an Overweight rating on Genocea with a $14 price target. Shares of the clinical-stage vaccine developer with a $227M market capitalization closed yesterday up 83c to $10.22.
06:15 EDTFITBFifth Third upgraded to Outperform from Perform at Oppenheimer
Subscribe for More Information
May 18, 2015
20:16 EDTANFUrban Outfitters down over 16% after disappointing Q1 results
Urban Oufitters (URBN) is down sharply after reporting first quarter earnings per share and revenue that missed analyst estimates. WHAT'S NEW: Urban Oufitters reported Q1 EPS of 25c on revenue of $739.01M, below consensus expectations of 30c and $758.25M, respectively. Urban Outfitters also reported Q1 comparable retail segment net sales up 4%, with Q1 retail segment net sales increasing 17% at Free People, 5% at Urban Outfitters, and 1% at the Anthropologie Group. Wholesale segment net sales rose 18%. WHAT'S NOTABLE: On its Q1 earnings conference call, Urban Outfitters announced that Urban Outfitters Group CEO Ted Marlow, who oversaw the direction of the namesake brand, would retire at the end of August. While Urban Outfitters did not provide guidance, Urban Outfitters Anthropologie Group CEO David McCreight commented on the Anthropologie brand, "We're expecting we could see Q2 shaping up like Q1 in terms of low single-digit comps. We could also see being in the low-mid-single digit comps. It's hard to tell at this point." ANALYST REACTION: Two analyst firms lowered their respective price targets on Urban Outfitters following the company's earnings report. Sterne Agee, which rates Urban Outfitters a Neutral, lowered its 12-month price target to $34 from $46, noting the company has had trouble getting both its Urban Outfitters and Anthropologie brands to perform at the same time. Cantor, which maintained its Buy rating, lowered its price target to $53 from $54, saying that Anthropologie sales disappointed, but noting that a "later catalog release appears to us to have pushed some sales at Anthropologie into May." PRICE ACTION: Urban Outfitters fell 16.4% to just over $34 in after-hours trading. PEERS: Other publicly traded companies in the space include Abercrombie & Fitch (ANF), American Eagle (AEO), Five Below (FIVE), Pacific Sunwear (PSUN), and Zumiez (ZUMZ).
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use